Antacids Market to Grow by USD 692.3 Million (2024-2028), Driven by Rising Geriatric Population, AI-Powered Report Explores Market Evolution - Technavio [Yahoo! Finance]
Cencora, Inc. (COR)
Last cencora, inc. earnings: 4/30 06:30 am
Check Earnings Report
US:NYSE Investor Relations:
investors.coresite.com/investor-overview
Company Research
Source: Yahoo! Finance
The market is estimated to grow at a CAGR of 3.27% during the forecast period. Rising geriatric population is driving market growth, with a trend towards growing e-commerce market. However, adverse effect of prolonged use of antacids poses a challenge.Key market players include Advance Pharmaceutical Inc., AmerisourceBergen Corp., Bayer AG, Cardinal Health Inc., GlaxoSmithKline Plc, Humco Holding Group Inc., inovapharma.com, Johnson and Johnson Services Inc., Neogen Corp., Novartis AG, NuCare Laboratories India, Pfizer Inc., Pharmaceutical Associates Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., The Procter and Gamble Co., United Natural Foods Inc., and WellSpring Pharmaceutical Corp.. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Antacids Market Scope Report Coverage Details Base year Historic period Forecast period Growth momentum & CAGR Accelerate at a CAGR of 3.27% Mark
Show less
Read more
Impact Snapshot
Event Time:
COR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COR alerts
High impacting Cencora, Inc. news events
Weekly update
A roundup of the hottest topics
COR
News
- Baltimore wins $266 million in opioid case against distributors [Yahoo! Finance]Yahoo! Finance
- Baltimore wins $266 million in opioid case against distributors [Yahoo! Finance Canada]Yahoo! Finance Canada
- U.S. Veterinary Surgical Disposables Market Report 2025-2030, Featuring VeterSut, B. Braun Vet Care, Vitrex Medical, AmerisourceBergen, Med-Vet International, Genia, Covetrus, Vedco and Phoenix Suture [Yahoo! Finance]Yahoo! Finance
- 2 drug companies to pay $260M after jury finds them liable for city's opioid crisis [CBS News]CBS News
- Cencora, Inc. (NYSE: COR) had its price target raised by analysts at Robert W. Baird from $287.00 to $292.00. They now have an "outperform" rating on the stock.MarketBeat
COR
Earnings
- 11/6/24 - Beat
COR
Sec Filings
- 11/13/24 - Form 4
- 11/13/24 - Form 4
- 11/13/24 - Form 4
- COR's page on the SEC website